2015 BCBSM HEDIS Measure Description PDF

2015
HEDIS MEASURE
DESCRIPTION
2015 HEDIS MEASURE DESCRIPTION
Table of Contents
OVERVIEW OF QUALITY INITIATIVES OF BCBSM AND BCN ............................................................................................................................................................... 4
PREVENTION AND SCREENING ........................................................................................................................................................................................................ 6
Adult Body Mass Index Assessment (ABA) ................................................................................................................................................................................... 6
Weight Assessment and Counseling for Nutrition And Physical Activity for Children/Adolescents (WCC) .............................................................................................. 7
Child Immunization Status (CIS) ................................................................................................................................................................................................... 8
Adolescent Immunizations (IMA) .............................................................................................................................................................................................. 11
Human Papillomavirus Vaccine for Female Adolescents (HPV)................................................................................................................................................... 12
Lead Screening in Children (LSC)................................................................................................................................................................................................ 12
Breast Cancer Screening (BCS) .................................................................................................................................................................................................. 13
Cervical Cancer Screening (CCS) ................................................................................................................................................................................................ 14
Colorectal Cancer Screening (COL) ............................................................................................................................................................................................ 15
Chlamydia Screening in Women (CHL) ....................................................................................................................................................................................... 16
Adult Health Maintenance Exam (HME) Complete History and Physical ................................................................................................................................. 18
Office Visits for People with Chronic Conditions ........................................................................................................................................................................ 20
IMMUNIZATIONS: Influenza Vaccine (Age 3 years and older) .................................................................................................................................................... 22
IMMUNIZATIONS: Pneumococcal Polysaccharide Vaccination .................................................................................................................................................. 22
Well-Child and Adolescent Well-Care Visits (W15, W34, AWC) .................................................................................................................................................. 23
RESPIRATORY CONDITIONS ........................................................................................................................................................................................................... 24
Use of Spirometry Testing in the Assessment and Diagnosis of Chronic Obstructive Pulmonary Disease - COPD (SPR) ............................................................... 24
1
March 2015

Use of Appropriate Medications for People with Asthma (ASM) ................................................................................................................................................ 25
Appropriate Treatment for Children With Upper Respiratory Infection (URI) NOT IN HEALTH e-BLUE ............................................................................................ 27
CONGESTIVE HEART FAILURE ........................................................................................................................................................................................................ 28
Congestive heart Failure (CHF) .................................................................................................................................................................................................. 28
DIABETES ...................................................................................................................................................................................................................................... 29
Comprehensive Diabetes Care (CDC) ......................................................................................................................................................................................... 29
MUSCULOSKELETAL CONDITIONS ................................................................................................................................................................................................. 32
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) ..................................................................................................................... 32
Osteoporosis Management in Women Who Had a Fracture (OMW) ......................................................................................................................................... 33
BEHAVIORAL HEALTH .................................................................................................................................................................................................................... 35
Antidepressant Medication Management (AMM) NOT IN HEALTH e-BLUE............................................................................................................................. 35
Follow-Up Care for Children Prescribed Attention Deficit/Hyperactivity Disorder Medication (ADD) ......................................................................................... 39
Follow-Up After Hospitalization for Mental Illness (FUH) NOT IN HEALTH e-BLUE .................................................................................................................. 45
MEDICATION MANAGEMENT ........................................................................................................................................................................................................ 47
Annual Monitoring for Patients on Persistent Medications (MPM) ........................................................................................................................................... 47
Potentially Harmful Drug-Disease Interactions in the Elderly (DDE) .......................................................................................................................................... 48
DRUG PLAN MEDICATION MONITORING CMS Part D Measures .................................................................................................................................................... 50
Recommended Blood Pressure Medications for Diabetics with Hypertension ........................................................................................................................... 50
High-Risk Medications in the Elderly.......................................................................................................................................................................................... 51
Medication Adherence to Oral Diabetes Medications ................................................................................................................................................................ 51
Medication Adherence for Hypertension (RAS Antagonists) ..................................................................................................................................................... 52
Medication Adherence for Cholesterol (Statins) ........................................................................................................................................................................ 52
ACCESS AND AVAILABILITY OF CARE .............................................................................................................................................................................................. 53
2
March 2015

Children and Adolescents Access to Primary Care Practitioners (CAP) NOT IN HEALTH e-BLUE .............................................................................................. 53
Prenatal and Postpartum Care (PPC) NOT IN HEALTH e-BLUE ................................................................................................................................................. 53
Adults Access to Preventive/Ambulatory Health Services (AAP) MAPPO Only ............................................................................................................................ 54
CMS MILLION HEARTS For Diabetes and Cardiovascular Disease (CVD) ......................................................................................................................................... 55
PATIENT DEMOGRAPHICS ............................................................................................................................................................................................................. 56
3
March 2015

OVERVIEW OF QUALITY INITIATIVES OF BCBSM AND BCN
Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network (BCN) are continuously working on improving the quality of care for our members. One way
quality of care can be verified is through industry standard performance measures. One of the more common quality measures is the Healthcare Effectiveness
Data and Information Set (HEDIS)*. It is a way to compare the quality of insurance plans based on the quality of care members receive using the same sets of
standards.
HEDIS requirements are established by the National Committee for Quality Assurance (NCQA). Annual reviews by NCQA are based on the same set of standards
for all insurance companies. HEDIS has become an integrated system that improves the accountability of the managed care industry with the ultimate goal of
improving the quality of care for members. HEDIS data is gathered by review of claims, medical records, supplemental data, and member surveys. It is valuable
for providers and their staff to be aware of the standards that are measured for HEDIS and how it is used to improve the quality of care for their patients.
Providers are encouraged to assist in the quality of care for their patients by carefully and accurately coding claims for their patients, as well as assuring
documentation is present in the medical records for the services provided. HEDIS measures can be updated by NCQA in an effort to continue to improve the
quality of care for members, and allow consumers the opportunity to compare plans with the same criteria being used.
CMS evaluates health insurance plans and issues Star ratings each year; these ratings may change from year to year. The CMS plan rating uses quality
measurements that are widely recognized within the health care and health insurance industry to provide an objective method for evaluating health plan
quality. The overall plan rating combines scores for the types of services BCBSM offers. CMS compiles its overall score for quality of services based on measures
such as:
How BCBSM/BCN help members stay healthy through preventive screenings, tests, and vaccines and how often our members receive preventive services
to help them stay healthy
How BCBSM/BCN help members manage chronic conditions
Scores of member satisfaction with BCBSM/BCN
How often members filed a complaint against BCBSM/BCN
How well BCBSM/BCN handles calls from members
4
March 2015
OVERVIEW OF QUALITY INITIATIVES OF BCBSM AND BCN (contd)

In addition, because BCBSM and BCN offer prescription drug coverage, CMS also evaluates BCBSMs and BCNs prescription drug plans for the quality of services
covered such as:
Drug plan customer service

Drug plan member complaints and Medicare audit findings
Member experience with drug plan
Drug pricing and patient safety
What are CMS Star ratings?

CMS developed a set of quality performance ratings for health plans that includes specific clinical, member perception, and operational measures. Percentile
performance is converted to Star ratings, based on CMS specifications, as one through five Stars, where five Stars indicate higher performance. This rating
system applies to all Medicare lines of business: health maintenance organizations, preferred provider organizations, and prescription drug plans. In addition,
their ratings are posted on the CMS consumers website, www.medicare.gov to help beneficiaries choose an MA plan offered in their area.
HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).
5
March 2015

PREVENTION AND SCREENING
Adult Body Mass Index Assessment (ABA)
MEASURE
Percentage of members between 18 and 74 years old who had an office visit and whose BMI was documented during the
measurement year or the year prior to the measurement year. Weight and BMI must come from the same data source.
EXCLUSIONS: Members with a diagnosis of pregnancy in the measurement year or the year prior to the measurement
year.
At least one BMI result recorded in the measurement year or the year prior to the measurement year.
WHAT SERVICE IS NEEDED
The Adult BMI Assessment should be part of a patients annual visit if they are between the ages of 18 and 74. Their
weight and BMI should be documented in their medical records.
Codes to identify office visits:
WHAT TO REPORT
HEDIS 2015 Measurement

Codes:
CPT: 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 9940199404, 99411, 99412, 99420, 99429, 99455, 99456
HCPCS: G0402, G0438, G0439, G0463
Codes to Identify BMI

ICD9-DIAG: V85.0-V85.45
Exclusions: .ICD9-DIAG: 630-679, V22, V23, V28
6
March 2015
Weight Assessment and Counseling for Nutrition And Physical Activity for Children/Adolescents (WCC)
MEASURE
The percentage of members, 3 - 17 years of age, who had an outpatient visit with a PCP or OB\GYN and who had
documentation of BMI Percentile, counseling for nutrition or counseling for physical activity during the measurement
year. Note that educational materials must be provided during a face to face visit in order to meet criteria for Counseling
for either NUTRITION or PHYSICAL ACTIVITY. Also, weight or obesity counseling count as numerator compliant for both
the Counseling for Nutrition and Counseling for physical activity indicators.
EXCLUSIONS: Members with a diagnosis of pregnancy in the measurement year or the year prior to the measurement year.
BMI percentile documentation, including height and weight, (evaluates whether BMI percentile is assessed rather
than an absolute BMI value), counseling for nutrition and counseling for physical activity during the measurement year.
For adolescents 16-17 years on the date of service, documentation of a BMI value expressed as kg/m2 is acceptable.
Codes to Identify Outpatient Visits

CPT: 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 9940199404, 99411, 99412, 99420, 99429, 99455, 99456
HCPCS: G0402, G0438, G0439, G0463
UB92 Revenue Codes: 051x, 0520-0523, 0526-0529, 0982, 0983
Codes to Identify BMI Percentile, Nutrition Counseling and Physical Activity Counseling
WHAT TO REPORT
HEDIS 2015Measurement
Codes:
Codes to Identify BMI Pediatric Percentile

ICD9- DIAGS: V85.51 Less than 5th percentile for age; V85.52 5th percentile to less than 85th percentile
for age
V85.53 = 85th percentile to less than 95th percentile for age; V85.54 Greater than or equal
to 95 percentile for age.
ICD9-DIAGS: BMI - V85.0 V85.45 ; Nutrition Counseling V65.3; Physical Activity Counseling - V65.41
HCPCS: Nutrition Counseling - G0270 G0271,G0447,S9449,S9452,S9470; Physical Activity Counseling -G0447,S9451
CPT: Nutrition Counseling - 97802, 97803, 97804
Exclusions:
ICD9-DIAGS: 630-679, V22, V23, V28
7
March 2015
Child Immunization Status (CIS)
MEASURE
Members who turn 2 years of age during the measurement year

Continuous Enrollment: Twelve months prior to the childs second birthday.
EXCLUSIONS: Members with anaphylactic reactions to any particular vaccine or its components.
Measles, Mumps and Rubella (MMR)*

At least one measles, mumps and rubella vaccine with a date of service on or before the second birthday
1. At least one measles and rubella vaccination AND at least one mumps vaccination OR history of the illness on the
same date of service or on different dates of service
2. At least one measles vaccination OR history of the illness AND at least one mumps vaccination OR history of the
illness AND at least one rubella vaccination OR history of the illness on the same date of service or on different dates
of service.
Chicken Pox (VZV)* At least one VZV vaccination on or before the childs 2nd birthday, or a documented history of chicken pox.
Polio (IPV)* At least 3 IPV vaccinations with different dates of service on or before the 2nd birthday. Do not count any IPV
administered prior to 42 days after birth.
Diphtheria, Tetanus, Pertussis (DtaP/DT)* At least four DTaP vaccinations, with different dates of service on or before the
2nd birthday. Do not count any vaccination administered prior to 42 days after birth.
Hepatitis (HepB)* At least 3 HepB vaccinations with different dates of service on or before the 2 nd birthday.
Hemophilus Influenza B (HiB)* At least 3 HiB vaccinations with different dates of service on or before the 2nd birthday. Do
not count any HiB administered prior to 42 days after birth.
8
March 2015

Childhood Immunizations (continued)
Pneumococcal (PCV) At least 4 pneumococcal conjugate vaccinations with different dates of service on or before the 2nd
birthday. Do not count any vaccination administered prior to 42 days after birth.
Hepatitis A One hepatitis A vaccination on or before the childs second birthday.
Rotavirus Acceptable combinations are: Two doses of two-dose vaccine, three doses of the three-dose vaccine or one dose
of the two-dose vaccine and two doses of the three-dose vaccine. The child must receive the required number of doses on
different dates of service, on or before the 2nd birthday. Do not count any vaccination administered prior to 42 days
after birth.
Influenza Two influenza vaccinations with different dates of service on or before the childs second birthday. Do not count
any vaccine administered prior to 6 months after birth.
Combo 2* Children who received DTaP/DT, IPV, MMR, HiB, HepB and VZV as described above.
Combo 3** Children who received DTaP/DT, IPV, MMR, HiB, HepB, VZV and PCV as described above.
Combo 10*** Children who received all listed vaccines as described above.
9
March 2015

Childhood Immunizations (continued)
WHAT TO REPORT
HEDIS2015
Measurement Codes:
DTaP
CPT: 90698, 90700, 90721, 90723
Polio (IPV)
CPT: 90698, 90713, 90723
MMR
CPT: 90710, 90707
Measles and Rubella
CPT: 90708
Measles
CPT: 90705
ICD9-DIAGS: 055, 0550, 0551, 0552, 05529, 0557, 05571, 05579, 0558, 05589, 0559
Mumps
CPT: 90704
ICD9-DIAGS: 072, 0720, 0721, 0722, 0723, 07251, 0727, 07271, 07272, 07279, 0728, 0729
Rubella
CPT: 90706
ICD9-DIAGS: 056, 0560, 05600, 05601, 05609, 0567, 05671, 05679, 0568, 0569
HiB
CPT: 90645-90648, 90698, 90721, 90748
Hepatitis B
CPT: 90723, 90740, 90744, 90747, 90748
HCPCS: G0010
ICD9-DIAGS: V02.61, 0702, 07020, 07021, 07022, 07023, 0703, 07030, 07031, 07032, 07033,
Chicken Pox (VZV)
CPT: 90710, 90716
ICD9-DIAGS: 052, 0520, 05209, 0521, 0522, 05230, 0527, 0528, 0529, 053, 0530, 0531, 05310, 05311, 05312, 05313,
05314, 05319, 0532, 05320, 05321, 05322, 05329
Pneumoccocal Conjugate
CPT: 90669, 90670
HCPCS: G0009
Hepatitis A
CPT: 90633
ICD9-DIAGS: 070.0, 070.1
Rotavirus (2 dose)
CPT: 90681
Rotavirus (3 dose)
CPT: 90680
Influenza
CPT: 90655, 90657, 90661, 90662
HCPCS: G0008
EXCLUSIONS: Anaphylactic reaction to any particular vaccine or its components. ICD9-DIAG: 999.42
10
March 2015
Adolescent Immunizations (IMA)
MEASURE
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Members who turn 13 years of age during the measurement year.

Continuous Enrollment: Twelve months prior to the childs thirteenth birthday.
EXCLUSIONS: Members with allergic reactions to any particular vaccine or its components. The exclusion must have
occurred by the members 13th birthday.
Meningococcal
One meningococcal conjugate or meningococcal polysaccharide vaccine on or between the members11th and 13th
birthdays
Tdap/Td
One tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) or one tetanus, diphtheria toxoids vaccine (Td)
on or between the members10th and 13th birthdays.
Combination # 1 (Meningococcal, Tdap, Td)
Adolescents who received one meningococcal vaccine on or between the members 11th and 13th birthday and one
tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) or one tetanus, diphtheria toxoids vaccine (Td) on or
between the members 10th and 13th birthdays.
Meningococcal
CPT: 90733, 90734
Tdap
CPT: 90715
Tetanus
CPT: 90703
Td
CPT: 90714, 90718
Diptheria
CPT: 90719
11
March 2015
EXCLUSIONS:
ICD9-DIAG: 999.42
Human Papillomavirus Vaccine for Female Adolescents (HPV)

The percentage of female adolescents 13 years of age who had three doses of the human papillomavirus (HPV) vaccine by
their 13th birthday.
MEASURE
Female adolescents who turn 13 years of age during the measurement year.
Continuous Enrollment: Twelve months prior to the members thirteenth birthday.
EXCLUSIONS: Members with anaphylactic reactions due to vaccine.
At least three HPV vaccinations with different dates of service on or between the members 9th and 13th birthdays.
WHAT TO REPORT
Human Papillomavirus Vaccine (HPV)

CPT: 90649, 90650
HEDIS 2015
Measurement Codes:
EXCLUSIONS:
ICD9-DIAG: 999.42
Lead Screening in Children (LSC)

MEASURE
Percentage of children 2 years of age who had one or more capillary or venous lead blood test for lead poisoning by their
second birthday.
EXCLUSIONS: None.

WHAT TO REPORT
HEDIS 2015
Measurement Codes:
At least one lead capillary or venous blood test on or before the childs second birthday as documented through either
administrative date (e.g., claim or lab report) or medical record review.
Medical record documentation must include the result or finding of the test.
Codes to identify lead screening:
CPT:
83655
Lead, quantitative; blood
12
March 2015
Breast Cancer Screening (BCS)

MEASURE
Percentage of women age 52 to 74 years old who have had a mammogram any time on or between October 1 two years
prior to the measurement year and December 31 of the measurement year.
EXCLUSIONS: Members with a bilateral mastectomy OR two unilateral mastectomies with service dates 14 or more days
apart.
One or more mammograms any time on or between October 1 two years prior to the measurement year and December
31 of the measurement year.
Codes to identify breast cancer screening (mammograms):
WHAT TO REPORT
Codes:
MEASURE
CPT: 77055-77057
HCPCS: G0202, G0204, G0206
UB2 Revenue Codes: 0401, 0403
Exclusions: Members with a bilateral mastectomy. Any of the following meet criteria for bilateral mastectomy:
Bilateral mastectomy
ICD9-PCS: 85.42, 85.44, 85.46, 85.48
Unilateral mastectomy with a bilateral modifier (50)

CPT: 1918050, 1920050, 1922050, 1924050, 1930350-1930750.
Two unilateral mastectomies with service dates 14 or more days apart.

Both of the following (on the same or a different date of service):
Unilateral mastectomy with a right-side modifier
Unilateral mastectomy with a left-side modifier
*50 modifier code indicates the procedure was bilateral and performed during the same operative session.
13
March 2015
Cervical Cancer Screening (CCS)

MEASURE
WHAT SERVICE
IS NEEDED
The percentage of women 24 64 years of age December 31 of the measurement year who were screened for cervical
cancer. See WHAT SERVICE IS NEEDED) for detail.
Continuous Enrollment: The measurement year and the two years prior to the measurement year.
EXCLUSIONS: Women who have had a total hysterectomy with no residual cervix.
For women 2464 years of age as of December 31 of the measurement year, a cervical cytology testing (PAP test).
Women age 24 64 who had cervical cytology performed every 3 years
Women age 35 64 who did not meet the first criteria who had cervical cytology AND human papillomavirus (HPV)
co-testing with service dates 4 or less days apart during the measurement year or the 4 years prior to the
measurement year and were 30 years or older on the date of both tests.
Codes to Identify Cervical Cancer Screening (Pap Test)
CPT: 88141-88143, 88147, 88148, 88150, 88152-88154, 88164-88167, 88174, 88175
HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091
UB2 REVENUE: 0923
WHAT TO REPORT
Codes:
Codes to Identify Human Papillomavirus Test

CPT: 87620, 87621, 87622
Codes to Identify Cervical Cancer Screening EXCLUSIONS (Hysterectomy with no residual cervix)
CPT: 51925, 56308, 58150, 58152, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285,
58290-58294, 58550- 58554, 58570 58573, 58951, 58953, 58954, 58956, 59135, 57540, 57545, 57555, 57550,
57556, 58548
ICD9-DIAGS: V88.01, V88.03, 618.5, 752.43
ICD9-PCS: 68.41, 68.49, 68.51, 68.59, 68.51, 68.69, 68.71, 68.79, 68.8
14
March 2015

Colorectal Cancer Screening (COL)
Percentage of members who are between 51 and 75 years old who had appropriate colorectal cancer screening.
MEASURE
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Continuous Enrollment: The measurement year and the year prior to the measurement year.
EXCLUSIONS: Members with a history of either a total colectomy or colon cancer.
Members between 51 and 75 years old with appropriate colorectal cancer screening:
One or more fecal occult blood (FOBT, gFOBT, or iFOBT) tests during the measurement year. OR
One or more flexible sigmoidoscopy procedures in the past 5 years OR
One or more colonoscopy procedures in the past 10 years NOTE: Clear documentation of previous colonoscopy or
sigmoidoscopy, including year performed, is required in medical record.
Codes to identify Colorectal Cancer Screening:
FOBT Fecal occult blood test (FOBT) CAN NOT be part of a digital rectal exam
CPT: 82270, 82274
HCPCS: G0328
Flexible sigmoidoscopy
CPT: 45330-45335, 45337-45342, 45345
HCPCS: G0104
Colonoscopy
CPT: 44388-44394, 44397, 45355, 45378-45387, 45391, 45392
HCPCS: G0105, G0121
Chart documentation of previously performed colorectal cancer screening tests.
Exclusions: Members with a history of either of the following:
MEASURE
Colorectal Cancer
HCPCS: G0213-G0215, G0231
ICD9-DIAGS: V10.05, V10.06, 153.0, 153.21, 153.2, 153.3, 153.4, 153.5, 153.7, 153.8, 153.9, 154, 154.1,
V154.2, 154.3, 197.5
Total Colectomy
CPT: 44150-44153, 44155-44158, 44210-44212
15
March 2015
Chlamydia Screening in Women (CHL)
MEASURE
The percentage of women 1624 years of age who were identified as sexually active and who had at least one test for
chlamydia during the measurement year.
Continuous Enrollment: The measurement year
EXCLUSIONS: Members who qualified for the denominator by pregnancy test alone during the measurement year AND
who meet either of the following:
A pregnancy test during the measurement year followed within seven days (inclusive) by either a prescription for
isotretinoin (Accutane) or an x-ray.
Women age 16 - 24 years who have been identified as sexually active and tested for Chlamydia
Female members aged 16 - 24 years who were identified as sexually active as of December 31 of the measurement year
Codes to Identify Chlamydia Screening
CPT: 87110, 87270, 87320, 87490, 87491, 87492, 87810
Identification of Sexually Active Women:
Two methods identify sexually active women: pharmacy data and claims/encounter data. A member only needs to be
identified by one method to be eligible for the measure.
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Pharmacy Data: Members who were dispensed prescription contraceptives during the measurement year.
Prescriptions to Identify Contraceptives
Contraceptive: desogestrel-ethinyl estradio, drospirenone-ethinyl estradio, estradiol-medroxyprogesterone, ethinyl
estradiol-ethynodiol, ethinyl estradiol-etonogestrel, ethinyl estradiol-levonorgestrel, ethinyl estradiol-norelgestromin,
ethinyl estradiol-norethindrone, ethinyl estradiol-norgestimate, ethinyl estradiol-norgestrel,etonogestrel,levonorgestrel,
medroxyprogesterone, mestranol-norethindrone,
Diaphragm: diaphragm
Spermacide: nonxynol
16
March 2015
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Claim/Encounter data. Members who had at least one encounter during the measurement year with any code listed
below.
CPT: 11976, 57022, 57170, 58300, 58301, 58600, 58605, 58611, 58615, 58970, 58974, 58976, 59000, 59001, 59012,
59015, 59020, 59025, 59030, 59050, 59051, 59070, 59072, 59074, 59076, 59100, 59120, 59121, 59130, 59135, 59136,
59140, 59150, 59151, 59160, 59200, 59300, 59320, 59325, 59350, 59400, 59409, 59410, 59412, 59414, 59425, 59426,
59430, 59510, 59514, 59515, 59525, 59610, 59612, 59614, 59618, 59620, 59622, 59812, 59820, 59821, 59830, 59840,
59841, 59850-59852, 59855-59857, 59866, 59870, 59871, 59897, 59898, 59899, 76801, 76805, 76811, 76813, 7681576821, 76825-76828, 76941, 76945-76946, 80055, 81025, 82105, 82106, 82143, 82731, 83632, 83661-83664, 84163,
86592-86593, 86631-86632, 87164, 87166, 87590-87592, 87620-87622, 87660, 87808, 87810, 87850, 88141-88143,
88147, 88148, 88150, 88152-88155, 88164-88167, 88174-88175, 88235, 88267, 88269, 81025, 84702, 84703
HCPCS: G0101, G0123, G0124, G0141, G0143-G0145, G0147, G0148, G0450, H1000, H1001, H1003-H1005, P3000,
P3001, Q0091, S0199, S4981, S8055
ICD9-DIAGS: 042, 054.10, 054.11, 054.12, 054.19, 078.11, 078.88, 079.4, 079.51-079.53, 079.88, 079.98, 091-097,
098.0, 098.10, 098.11, 098.15-098.19, 098.2, 098.30, 098.31, 098.35-098.8, 099, 131,302.76,339.82,602.76, 625.0,
614-615, 622.3, 623.4, 626.7, 628, 630-679, 795.0, 795.1, 796.7, 996.32, V01.6, V02.7, V02.8, V08, V15.7, V22-V25,
V26.0-V26.4, V26.51, V26.8, V26.9, V27, V28, V45.5, V61.5-V61.7, V69.2, V72.3, V72.4, V73.81, V73.88, V73.98, V74.5,
V76.2
ICD9-PCS: 69.01, 69.02, 69.51, 69.52, 69.7, 72-75, 88.78, 97.24, 97.71, 97.73
UB Revenue: 0112, 0122, 0132, 0142, 0152, 0720-0722, 0724, 0729, 0923, 0925
Codes/Medications to Identify Exclusions:
Description
CPT
UB2 Revenue
Pregnancy test
Diagnostic
radiology
Description
Retinoid
81025, 84702,
84703
WITH
0925
70010-76499
032x
Prescription
Isotretinoin
17
March 2015

Adult Health Maintenance Exam (HME) Complete History and Physical
Percent of adult members who had a HME (health maintenance examination) with a specialty designated by BCN during
the measurement year.
MEASURE
This is a BCN Clinical Guideline measure for BCN and Medicare (BCNA).
Reporting age ranges, 22-49, 50-64 and 65 and over, follow Michigan Quality Improvement Consortium (MQIC) and
BCN Clinical Guidelines.
Members 22 years of age or older as of December 31 of the measurement year
Continuous Enrollment: The measurement year.
Claims data only is used to look for Health Maintenance Exams (HMEs). HEDIS 2015 Adult Access to Preventive
/Ambulatory Health Service and selected Adolescent Well Care Visit codes are used to identify HMEs. The servicing
provider must have a specialty as outlined below.
Adult members who had a HME (health maintenance examination) with a specialty designated by BCN during the
measurement year.
22-49 years
1 HME in the last five years
50-64 years
1 HME in the last three years
65 years or older 1 HME in the last 2 years
Codes to Identify Health Maintenance Exams
WHAT TO REPORT
This is a BCN Clinical
Guideline Measure
Preventive Office Visits:

CPT:
99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99420, 99429
HCPCS: G0402, G0438, G0439, G0463
General Medical Examination
ICD9-DIAGS: V70.0, V70.3, V70.5, V70.6, V70.8, V70.9, V20.2, V20.3, V20.31, V20.32
18
March 2015

Adult Health Maintenance Exam (contd)
WHAT TO REPORT
This is a BCN Clinical
Guideline Measure
Designated Provider Specialties for HME

Adolescent Medicine
Cardiovascular Disease
Endocrinology
Family Nurse Practitioner
General Practice
Geriatric Medicine Internal Medicine
Internal Medicine
Nephrology
Obstetrics
Pediatric Cardiology
Pediatric Nephrology
Pediatrics
Geriatric Nurse Practitioner
Cardiology
Certified Nurse Practitioner
Endocrinology, Diabetes, Metabolism
Family Practice
Geriatric Medicine-Family Practice
Gynecology
Internal Medicine - Pediatric
Ob/Gyn Nurse Practitioner
Obstetrics & Gynecology
Pediatric Endocrinology
Pediatric Nurse Practitioner
Preventive Medicine
19
March 2015

Office Visits for People with Chronic Conditions
Diseases vary by product:
BCN-COMMERCIAL: Asthma, diabetes, CVD, CHF, COPD
BCN-ADVANTAGE: Diabetes, CVD, CHF, COPD
Age ranges by disease:
MEASURE
ASTHMA
DIABETES
CVD
CHF
COPD
5 64 years
18 - 75 years
18 - 75 years
18 years and over
40 years and over
Continuous Enrollment: Measurement year.

PROCESS:
Use claims to look for Outpatient Preventive Office Visits, using selected codes from HEDIS 2015 Adult Access to
Preventive/Ambulatory Health Services and the Children and Adolescents Access to Primary Care Practitioners) and
the Place of Service codes indicated (see list of codes).
For office or other outpatient services, preventive medicine and general medical examinations, the provider must
also have a specialty consistent with a PCP or other specialist specialty (see list of specialties).
Revenue codes have been removed because they are non-specific.
Two or more outpatient preventive office visits during the measurement year for members with one or more of the
following chronic diseases: asthma, diabetes, cardiovascular disease (CVD), congestive heart failure (CHF), chronic
obstructive pulmonary disease (COPD), regardless of diagnosis
Office Visits for People with Chronic Conditions
WHAT TO
REPORT
Office or other outpatient services (with specific specialty below)

CPT: 99201-99205, 99211-99215, 99241-99245
Home services:
CPT: 99341-99345, 99347-99350
Nursing facility care:
CPT: 99304-99310, 99315-99316, 99318
20
March 2015

Office Visits For People with Chronic Conditions (contd)
Domiciliary, rest home or custodial care services:
CPT: 99324-99328, 99334-99337
WHAT TO
REPORT
Preventive medicine (with specific specialty below)

CPT: 99381-99387, 99391-99397, 99401-99404, 99411-99412, 99420, 99429, 99461
HCPCS: G0344 (historical), G0402, G0438, G0439, G0463
General medical examination (with specific specialty below)
ICD9-DIAGS: V20.2, V20.3, V70.0, V70.3, V70.5, V70.6, V70.8, V70.9
PROVIDER SPECIALITY
BCN
ADO
CARD
CVD
CNP
ENDO
EDM
NPF
FP
GP
GMFP
EDM
NPF
FP
GP
GMFP
EDM
NPF
FP
OBGY
PECA
PEEN
PENE
NPP
PED
PREM
PLACE OF SERVICE CODES (POS)
Description
ADOLESCENT MEDICINE
CARDIOLOGY
CARDIOVASCULAR DISEASE
CERTIFIED NURSE PRACTITIONER
ENDOCRINOLOGY
ENDOCRINOLOGY, DIABETES, METAB
FAMILY NURSE PRACTITIONER
FAMILY PRACTICE
GENERAL PRACTICE
GERIATRIC MEDICINE-FAMILY PRAC
FAMILY PRACTICE
GENERAL PRACTICE
GERIATRIC MEDICINE-FAMILY PRAC
FAMILY PRACTICE
OBSTETRICS & GYNECOLOGY
PEDIATRIC CARDIOLOGY
PEDIATRIC ENDOCRINOLOGY
PEDIATRIC NEPHROLOGY
PEDIATRIC NURSE PRAC
PEDIATRICS
PREVENTIVE MEDICINE
POS
04
05
06
07
08
11
12
13
14
15
22
26
31
32
33
34
49
50
54
71
72
21
March 2015
Description
HOMELESS SHELTER
INDIAN HEALTH SERVICE FREE STANDING FACILITY
INDIAN HEALTH SERVICE PROVIDER BASED FACILITY
TRIBAL 638 FREE STANDING FACILITY
TRIBAL 638 PROVIDER BASED FACILITY
OFFICE
HOME
ASSISTED LIVING FACILITY
GROUP HOME
MOBILE UNIT
OUTPATIENT HOSPITAL
MILITARY TREATMENT CENTER
SNF
NURSING FACILITY
CUSTODIAL CARE
HOSPICE
INDEPENDENT CLINIC
FEDERALLY QUALIFIED HEALTH CENTER
INTERMEDIATE CARE FACILITY MENTALLY RETARDED
PUBLIC HEALTH CLINIC
RURAL HEALTH CLINIC
IMMUNIZATIONS: Influenza Vaccine (Age 3 years and older)

MEASURE
Percent of members 3 years of age or older during the measurement year, who had a flu shot between July and
December of the measurement year. NOTE: Influenza vaccines administered at pharmacies are billed to BCN and included.
EXCLUSIONS: Members with anaphylactic reactions due to vaccine.
One influenza vaccine during the measurement year.

Codes to Identify Influenza Vaccine
WHAT TO REPORT
CPT: 90654, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90663, 90724 (historical), 90659, 90471
HCPCS: G0008, G9141, G9142, Q2035, Q2036, Q2037, Q2038, Q2039
ICD9-PCS: 99.52
Codes to Identify Exclusions:

ICD9-DIAGS: 999.42
MEASURE
BCN Advantage
Members ONLY
WHAT TO REPORT
IMMUNIZATIONS: Pneumococcal Polysaccharide Vaccination

Percentage of BCN Advantage members who have ever received a pneumonia vaccine.
EXCLUSIONS: Members with an anaphylactic reaction due to vaccine.
One pneumococcal polysaccharide vaccine in a members history.
Codes to Identify Pneumococcal Polysaccharide Vaccine

CPT: 90732
HCPCS: G0009
EXCLUSIONS: 999.42
22
March 2015
Well-Child and Adolescent Well-Care Visits (W15, W34, AWC)

Percentage of children with 6 or more well-child visits in the first 15 months of life, one or more well child visits between 3
6 years and one or more well-child visits between 12 and 21 years of life.
MEASURE
Well child visits must be with a PCP or an OB/GYN for Adolescent Well Care.
First 15 months of life, 3-6 years of age, 12 - 21 years of age as of December 31 of the measurement year.
Continuous Enrollment: 31 days of age through 15 months, or the measurement year for 3 6 years and 12 21
years.
Well-Care Visits: First 15 mos.

6 or more well care visits with a primary care physician in the first 15 months of life with different dates of service.
Well-Care Visits: 3 6 years

1 or more well-care visits with a primary care physician during the measurement year.
Well-Care Visits: 12 21 years (Adolescent Well Care)
1 or more well-care visits with a primary care physician or OB/GYN practitioner during the measurement year.
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Codes to Identify Well-Care Visits
ICD9-DIAGS: V20.2, V20.3, V20.31, V20.32, V70.0, V70.3, V70.5, V70.6, V70.8, V70.9
CPT: 99381, 99382, 99383, 99384, 99385, 99391, 99392-99395, 99461
HCPCS: G0438, G0439
23
March 2015

RESPIRATORY CONDITIONS
Use of Spirometry Testing in the Assessment and Diagnosis of Chronic Obstructive Pulmonary
Disease - COPD (SPR)
The percentage of members 40 years of age and older with a new diagnosis or newly active COPD who received
appropriate spirometry testing to confirm the diagnosis.
MEASURE
Intake Period: a 12 month window that begins January 1 of the measurement year and ends on December 31 of
the measurement year. The intake period captures the first COPD diagnosis.
Index episode start date (IESD): The earliest date of service for an eligible visit during the intake period with any
diagnosis of COPD.
Negative diagnosis history: A period of 730 days (2 years) prior to the IESD (inclusive), when the member had no
claims/encounters containing any diagnosis of COPD
Continuous enrollment: 730 days (2 years) prior to the IESD through 180 days after the IESD.
EXCLUSIONS: Members who do not meet the Negative diagnosis history criteria
At least one spirometry testing in the 730 days (2 years) before the index episode start date of COPD to 180 days after
the index episode start date of COPD.
ICD9-DIAGS to Identify COPD
WHAT TO REPORT
COPD - 493.20, 493.21, 493.22, 496,

Chronic Bronchitis 491.0, 491.1, 491.20, 491.21, 491.22, 491.8, 491.9
Emphysema 492.0, 492.8

Codes
Codes to Identify Spirometry Testing

CPT: 94010, 94014-94016, 94060, 94070, 94375, 94620
24
March 2015
Use of Appropriate Medications for People with Asthma (ASM)

The percentage of members 564 years of age during the measurement year who were identified as having persistent
asthma and who were appropriately prescribed medication during the measurement year.
MEASURE
HEDIS 2015 definition of persistent asthma

Members between 5 and 64 years by December 31 of the measurement year.
Continuous Enrollment: The measurement year and the year prior to the measurement year.
Members identified as having persistent asthma who met at least one of the following criteria during both the
measurement year AND the year prior to the measurement year:
1 inpatient admission with primary diagnosis of asthma OR
1 emergency department visit with primary diagnosis of asthma OR
4 or more outpatient asthma visits with asthma listed as one of the diagnoses AND at least 2 asthma
medication dispensing events OR
4 asthma medication dispensing events*
All inhalers (canisters) of the same medication dispensed on the same day count as one dispensing event.
Medications with different Drug Ids dispensed on the same day are counted as different dispensing events.
*A member identified as having persistent asthma because of at least four asthma medication dispensing events, where
leukotriene modifiers or antibody inhibitors were the sole asthma medication dispensed in that year must also have at
least one diagnosis of asthma in any setting in the same year as the leukotriene modifier or antibody inhibitor.
EXCLUSIONS: Members with ICD -9-CM Diagnosis codes for emphysema or COPD, or cystic fibrosis, or acute respiratory
failure.
Dispensed at least one prescription for an asthma controller medication during the measurement year (30 day supply)
Anti-asthmatic combinations, antibody inhibitor, Inhaled corticosteroids, Inhaled steroid combinations, Mast cell
stabilizers, Leukotriene modifiers or Methylxanthines
Use of Appropriate Medications For People with Asthma (contd)

25
March 2015

Codes to Identify asthma
ICD9-DIAGS for asthma (493.xx)
493.01, 493.02, 493.10, 493.11, 493.12, 493.81, 493.82, 493.90, 493.91, 493.92
Codes for Disease Identification: Outpatient/Ambulatory Preventive Visits
CPT: 99201-99205, 99211-99215, 99315, 99316, 99241-99245, 99341- 99345, 99347-99350, 99304-99310, 99318,
99324-99328, 99334-99337, 99381-99387, 99391-99397,99401-99404,99411, 99412, 99420, 99429
ICD9-DIAGS: V70.0, V70.3, V70.5, V70.6, V70.8, V70.9, V20.2
HCPCS: G0402, G0438, G0439, S0621, G0463
UB-92 Revenue: 051x, 0520-0523, 0526-0529, 0982, 0983
Asthma Controller Medications
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Antiasthmatic combinations: Guaifenesin-theophylline, Dyphylline-guaifenesin
Antibody inhibitor: Omalizumab
Inhaled steroid combination: Budesonide-formoterol, Fluticasone-salmeterol, Mometasone-formoterol
Inhaled corticosteroids: Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone CFC free, Mometasone,
Triamcinolone
Leukotriene modifiers: Montelukast, Montelukast, Zileuton
Mast cell stabilizers: Cromolyn
Methylxanthines: Aminophylline, Dyphylline, Theophyllin
NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by November 1, 2014.
26
March 2015

Use of Appropriate Medications for People with Asthma (contd)
WHAT TO REPORT
Codes:
EXCLUSIONS: ICD9-DIAGS Emphysema: 492.0, 492.8, 518.1, 518.2

Cystic Fibrosis: 277.0, 277.01, 277.02, 277.03, 277.09
COPD: 493.20, 493.21, 493.22, 496
Chronic Respiratory Conditions Due to Fumes/Vapors: 506.4
Acute respiratory Failure: 518.81
Chronic Obstructive Bronchitis: 491.2, 491.21, 493.22
Appropriate Treatment for Children With Upper Respiratory Infection (URI) NOT IN HEALTH e-BLUE
MEASURE
Percentage of children 3 months 18 years of age who were given a diagnosis of upper respiratory infection (URI) and
were NOT dispensed and antibiotic prescription.
EXCLUSIONS: Episodes where the member had a claim/encounter with a competing diagnosis on or three days after
another episode date.
None.
WHAT TO REPORT
NA

Codes:
27
March 2015

CONGESTIVE HEART FAILURE
Congestive heart Failure (CHF)
Percent of members with CHF who had two or more preventive office visits during the measurement year.
Disease Identification:
MEASURE
Members age18 years and over as of December 31 of the measurement year.

Members with:
1 inpatient admission with a primary or secondary diagnosis of CHF OR
1 emergency department visit with a primary or secondary diagnosis CHF OR
3 outpatient encounters with a diagnosis sof CHF OR
Prescriptions for ACEI/ARB and Digoxin and a Diuretic within a 90-day window of each other.
Continuous Enrollment: The measurement year
Two or more office visits in the measurement year

Codes to identify CHF:
ICD9-DIAGS: 402.11, 402.01, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.9
WHAT TO REPORT
HEDIS 2015
Measurement Codes:

CPT: 99201-99205, 99211-99215, 99315, 99316, 99241-99245, 99341- 99345, 99347-99350, 99304-99310, 99318,
99324-99328, 99334-99337, 99381-99387, 99391-99397,99401-99404,99411, 99412, 99420, 99429
HCPCS: G0402, G0438, G0439, S0621, G0463
UB-92 Revenue: 051x, 0520-0523, 0526-0529, 0982, 0983
28
March 2015

DIABETES
Comprehensive Diabetes Care (CDC)
The percentage of members, 1875 years of age as of December 31 of the measurement year, with diabetes (type 1 and
type 2) who had each of the following:
Hemoglobin A1c (HbA1c) testing
Eye exam (retinal) performed.
Good HbA1c Control (<= 9.0%)
Medical attention for nephropathy
HbA1c control (<8.0%)
MEASURE
HEDIS2015 definition of diabetes (type 1 and 2)
Members are identified as having diabetes as follows:

1 inpatient admission with a primary or secondary diagnosis of diabetes OR
2 emergency department visit with a primary or secondary diagnosis of diabetes OR
2 outpatient encounters with a diagnosis of diabetes in the measurement year or year prior to the measurement
year OR
A prescription for insulin or an oral hypoglycemic/antihyperglycemic the measurement year or year prior to the
measurement year. NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by
November 1, 2014.
EXCLUSIONS: Patients with a diagnosis of gestational diabetes, polycystic ovaries, or steroid induced diabetes.
Retinal Eye Exam performed by an Eye Care Professional

One exam in the measurement year or a negative exam in the previous year
Nephropathy Screening Test (Micro Albumin test)

A nephropathy screening test during the measurement year.
Evidence of Treatment for Nephropathy

A positive macroabluminuria test in the measurement year OR
A visit with a nephrologist OR
Evidence of ACE inhibitor/ARB therapy during the measurement year OR
Evidence of Nephropathy
29
March 2015

Diabetes (continued)
Hemoglobin (HbA1c) A1c tested

One or more tests performed during the measurement year.
HbA1c Good Control <= 9 %
The most recent HbA1c level performed during the measurement year is <= 9.0%
HbA1c Control < 8.0%
The most recent HbA1c level performed during the measurement year is < 8.0%
Codes to Identify members with diabetes

ICD9-DIAGS: 250.xx, 357.2X, 362.0X, 366.41, 648.0X
CPT: 99201-99205, 99211-99215, 99315, 99316, 99241-99245, 99341- 99345, 99347-99350, 99304-99310,
99318, 99324-99328, 99334-99337, 99381-99387, 99391-99397,99401-99404,99411, 99412, 99420, 99429
HCPCS: G0402, G0438, G0439, S0621, G0463
UB-92 Revenue: 051x, 0520-0523, 0526-0529, 0982, 0983
WHAT TO REPORT
HEDIS2015 Measurement
Codes:
Codes to Identify HbA1c Tests

CPT: 83036, 83037
CPT Category II: 3044F, 3045F, 3046F
Codes to Identify Nephropathy Screening Tests

CPT: 82042, 82043, 82044, 84156
CPT CATEGORY II: 3060F, 3061F
Codes to Identify Evidence of Nephropathy
Urine Macro albumin, positive
CPT: 81000-81003, 81005
CPT CATEGORY II: 3062F
30
March 2015

Diabetes (continued)
Evidence of Treatment for Nephropathy
WHAT TO REPORT
HEDIS2015
Measurement Codes:
CPT: 36147, 36800, 36810, 36815, 36818, 36819-36821, 36831-36833, 50300, 50320, 50340, 50360, 50365,
50370, 50380, 90935, 90937, 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 90957-90962, 90965,
90966, 90969, 90970
CPT CATEGORY II: 3066F
HCPCS: G0257, S9339, S2065
ICD9-DIAGS: 250.4, 403, 404, 405.01, 405.11, 405.91, 580-588, 753.0, 753.1, 791.0, V45.1
ICD9-PCS: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, 55.6
UB2 REVENUE: 0367, 080x, 082x-085x, 088x
PLACE OF SERVICE (POS): 65
ACE/ARB
CPT CATEGORY II: 4010F Refer to www.ncqa.org for a comprehensive list of medications and NDCs.
Diagnosis of:
Refer to www.ncqa.org for a complete list of diagnosis codes.
Chronic Kidney Disease
ESRD
Kidney Transplant
Codes to Identify Eye Exams (Must be with or evaluated by an Eye Care Professional)
CPT: 67028, 67030, 67031, 67036, 67039-67043, 67101, 67105, 67107, 67108, 67110, 67112, 67113, 67121,
67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92012, 92014, 92018, 92019,
92225, 92226, 92230, 92235, 92240, 92250, 92260, 99203-99205, 99213-99215, 99242-99245, 92134, 92227,
92228, 92134
CPT CATEGORY II: 2022F, 2024F, 2026F, 3072F
HCPCS: S0625, S3000, S0620, S0621
Exclusions: ICD9-DIAGS Refer to www.ncqa.org for a complete list of diagnosis codes.
Polystic Ovaries 256.4

Gestational Diabetes 648.8
Steroid-Induced Diabetes 249, 962.0, 251.8
31
March 2015

MUSCULOSKELETAL CONDITIONS
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)
MEASURE
The percentage of members ages 18 and over diagnosed with Rheumatoid Arthritis and who were dispensed at least
one ambulatory prescription for a disease modifying anti-rheumatic drug (DMARD).
Event/diagnosis: Two face-to-face encounters with different dates of service in an outpatient or non-acute
inpatient setting on or between January 1 and November 30 of the measurement year with any diagnosis of
rheumatoid arthritis.
EXCLUSIONS: A diagnosis of HIV anytime during the members history through December 31 of the measurement year.
A diagnosis of pregnancy anytime during the measurement year.
One or more DMARD prescription during the measurement year.
Codes to Identify Rheumatoid Arthritis
ICD9-DIAGS: 714.0, 714.1, 714.2, 714.81
Exclusions: Refer to www.ncqa.org for a complete list of diagnosis codes.
HIV: ICD9-DIAGS: 042, V08
Pregnancy: ICD9-DIAGS: 630679, V20, V22, V28
DMARDs: NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by November 1, 2014.
WHAT TO REPORT
Codes:
Description
5-Aminosalicylates
Alkylating agents
Aminoquinolines
Anti-rheumatics
Immunomodulators
Immunosuppressive
agents
Jnaus Kinase (JAK)
inhibitor
Tetracyclines
Prescription
Sulfasalazine
Cyclophosphamide
Hydroxychloroquine
Auranofin
Gold sodium thiomalate
Abatacept
Adalimumab
Anakinra
Certolizumab
Azathioprine
Tofactinib
Minocycline
32
March 2015
J Code
Leflunomide
Penicillamine
Methotrexate
Certolizumab pegol
Infliximab
Etanercept
Rituximab
Golimumab
Tocilizumab
J1600, J9250, J9260
Cyclosporine
J7502, J7515, J7516, J7517,

J7518
Mycophenolate
J0129, J0135, J0718, J1438,

J1745, J9310, J0717, J1602
J3262
Osteoporosis Management in Women Who Had a Fracture (OMW)

The percentage of women 67 85 years of age who suffered a fracture and who had EITHER a bone mineral density
(BMD) test OR a prescription for a drug to treat or to prevent osteoporosis in the six months after the fracture.
MEASURE
Women 67 years 85 years of age as of December 31 of the measurement year.

Continuous Enrollment: 12 months before the initial fracture date through 6 months after the initial fracture
date.
Appropriate testing or treatment for osteoporosis after the fracture defined by any of the following criteria:
A BMD test on the initial fracture date (IESD) or in the 180-day period after the initial fracture date OR
A BMD test during the inpatient stay for the fracture (applies only to fractures requiring hospitalization)
OR
A dispensed prescription to treat osteoporosis on the initial fracture date or in the 180 day period after the initial
fracture date.
EXCLUSIONS: Exclude members who had a BMD, or a claim/encounter for osteoporosis therapy or received a
dispensed prescription to treat osteoporosis during the 365 days prior to the IESD.
One or more of the following: (1) a BMD test or (2) osteoporosis prevention/treatment prescription in the six months
after the fracture.
Codes for Fractures Fractures of finger, toe, face, skull and pathological fractures are not included in this measure.
WHAT TO REPORT
HEDIS2015
Measurement Codes:
HCPCS: S2360
ICD9-DIAGS: 733.1, 733.93-733.98, 805-806, 807.0-807.4, 808-815, 818-825, 827, 828
ICD9-PCS: 79.01-79.03, 79.05-79.07, 79.11-79.13, 79.15-79.17, 79.21-79.23, 79.25-79.27, 79.31-79.33, 79.3579.37, 79.61- 79.63, 79.65-79.67, 81.65, 81.66
33
March 2015
Osteoporosis Management in Women Who Had A Fracture (contd)

Codes for Fractures Fractures of finger, toe, face, and skull are NOT included in this measure.
WHAT TO REPORT
HEDIS2015 Measurement
Codes:
CPT: 21800, 21805, 21810, 21820, 21825, 22305, 22310, 22318, 22319, 22520, 22521, 22523, 22524, 23500, 23505, 23515,
23570, 23575, 23585, 23600, 23605, 23615, 23616, 23620, 23625, 23630, 23665, 23670, 23675, 23680, 24500, 24505, 24515,
24516, 24530, 24535, 24538, 24545, 24546, 24560, 24565, 24566, 24575-24577, 24579, 24582, 24620, 24635, 24650, 24655,
24665, 24666, 24670, 24675, 24685, 25500, 25505, 25515, 25520, 25525, 25526, 25530, 25535, 25545, 25560, 25565, 25574,
25575, 25600, 25605-25609, 25622, 25624, 25628, 25630, 25635, 25645, 25650, 25651, 25652, 25680, 25685, 26600, 26605,
26607, 26608, 26615, 27193, 27194, 27200, 27202, 27215-27218, 27220, 27222, 27226-27228, 27230, 27232, 27235, 27236,
27238, 27240, 27244, 27245, 27246, 27248, 27254, 27267-27269, 27500-27503, 27506-27511, 27513, 27514, 27520, 27524,
27530, 27532, 27535, 27536, 27538, 27540, 27750, 27752, 27756, 27758-27760, 27762, 27766- 27769, 27780, 27781, 27784,
27786, 27788, 27792, 27808, 27810, 27814, 27816, 27818, 27822-27828, 28400, 28405, 28406, 28415, 28420, 28430, 28435,
28436, 28445, 28450, 28455, 28456, 28465, 28470, 28475, 28476, 28485, 29850, 29851, 29855, 29856
FDA-Approved Osteoporosis Therapies

Description
Biphosphonates
Other Agents
Prescription
alendronate
alendronate-cholecalciferol
zoledronic acid
calcitonin
denosumab
Codes to Identify Bone Mineral Density Test
WHAT TO REPORT
CPT: 76977, 77078, 77080-77082,

HCPCS: G0130
ICD9-PCS: 88.98
34
March 2015
ibandronate
risedronate
calcium carbonate-risedronate
raloxifene
teriparatide
J Code
J3488,
J3487,
J1740, J3489
J0630, J3110,
J0897

BEHAVIORAL HEALTH
Antidepressant Medication Management (AMM) NOT IN HEALTH e-BLUE
The percentage of members 18 years of age and older as of April 30 of the measurement year, with a diagnosis of major
depression and were newly treated with antidepressant medication, and who remained on an antidepressant
medication treatment. Two rates are reported
Effective Acute Phase Treatment. The percentage of members who remained on an antidepressant medication for
at least 84 days (12 weeks).

Effective Continuation Phase Treatment. The percentage of members who remained on an antidepressant
medication for at least 180 days (6 months)
Continuous Enrollment: 105 days prior to the IPSD through 231 days after the IPSD.
MEASURE
EXCLUSIONS: Exclude members who did not have a diagnosis of major depression as described below in Step 2
Required Exclusion in determination of eligible population.
Definitions
Intake Period
The 12-month window starting on May 1 of the year prior to the measurement year and
ending on April 30 of the measurement year.
ISPD
Index Prescription Start Date. The earliest prescription dispensing date for an
antidepressant medication during the Intake Period.
Negative
Medication
History
A period of 105 days prior to the IPSD when the member had no pharmacy claims for
either new or refill prescriptions for an antidepressant medication.
Treatment
Days
The actual number of calendar days covered with prescriptions within the specified 180day (6-month) measurement interval. For Effective Continuation Phase Treatment, a
prescription of 90 days (3 months) supply dispensed on the 151st day will have 80 days
counted in the 231-day interval.
35
March 2015

Antidepressant Medical Management (contd)
Event/Diagnosis: Follow the steps below to identify the eligible population, used for both rates
Step 1
Step 2:
Required
exclusion
MEASURE
Determine the IPSD. Identify the date of the earliest dispensing event for an
antidepressant medication during the Intake Period.
Exclude members who did not have a diagnosis of major depression in an inpatient,
outpatient, ED, intensive outpatient or partial hospitalization setting during the 60 days
prior to the IPSD (inclusive) through 60 days after the IPSD (inclusive). Members who meet
any of the following criteria remain in the eligible population:
An outpatient visit, intensive outpatient encounter or partial hospitalization with
any diagnosis of major depression.

An ED visit with any diagnosis of major depression.
An inpatient (acute or non-acute) encounter with any diagnosis of major depression.
For an inpatient (acute or non-acute) encounter, use the date of discharge.

For a direct transfer, use the discharge date from the facility where the member was
transferred.
Event Diagnosis:
Step 3 Test for Negative Medication History. Exclude members who filled a prescription for an
antidepressant medication 105 days prior to the IPSD.
Step 4 Calculate continuous enrollment. Members must be continuously enrolled for 105 days
prior to the IPSD to 231 days after the IPSD.
36
March 2015

Effective Acute Phase Treatment.
At least 84 days (12 weeks) of continuous treatment with antidepressant medication during the 114-day period following
the IPSD (inclusive). The continuous treatment allows gaps in medication treatment up to a total of 30 days during the
114-day period. Gaps can include either washout period gaps to change medication or treatment gaps to refill the same
medication.
Regardless of the number of gaps, there may be no more than 30 gap days. Count any combination of gaps (e.g. two
washout gaps of 15 days each, or two washout gaps of 10 days each and one treatment gap of 10 days).
Effective Continuation Phase Treatment
At least 180 days (6 months) of continuous treatment with antidepressant medication
during the 231-day period following the IPSD (inclusive). Continuous treatment allows gaps in the medication treatment
up to a total of 51 days during the 231 day period. Gaps can include either washout period gaps to change medication or
treatment gaps to refill the same medication.
Codes to Identify Major Depression Refer to www.ncqa.org for a complete list of diagnosis codes.
WHAT TO REPORT
ICD9-DIAGS: 296.20 - 296.25, 296.30 - 296.35, 298.0, 311
Antidepressant Medications:
HEDIS 2015
Measurement Codes:
Description
Miscellaneous
antidepressants
Monoamine
oxidase inhibitors
Prescription
Bupropion
Vilazodone
Selegiline
Tranylcypromine
Isocarboxazid
Phenelzine
37
March 2015

WHAT TO REPORT
Codes:
Description
Phenylpiperazine
antidepressants
Psychotherapeutic
combinations
SSNRI
antidepressants
SSRI
antidepressants
Tetracyclic
antidepressants
Tricyclic
antidepressants
Prescription
Nefazodone
Amitriptyline-chlordiazepoxide
Amitriptyline-perphenazine
Desvenlafaxine
Duloxetine
Citalopram
Fluoxetine
Escitalopram
Fluvoxamine
Maprotiline
Mirtazapine
Amitriptyline
Amoxapine
Clomipramine
Desipramine
Doxepin
Imipramine
Trazodone
Fluoxetine-olanzapine
Venlafaxine
Paroxetine
Sertraline
Nortriptyline
Protriptyline
Trimipramine
38
March 2015

Follow-Up Care for Children Prescribed Attention Deficit/Hyperactivity Disorder Medication (ADD)
Quality Summary Report Measure Only (no data entry in Treatment Opportunities by Condition/Measure)
HEDIS2015 for more details on the medications in this measure, please reference the NCQA 2015
HEDISspecifications@ncqa.org.
The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at
least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD
medication was dispensed. Two rates are reported.
MEASURE
Rate 1: Initiation Phase. The percentage of members 612 years of age as of the IPSD with an ambulatory
prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing
authority during the 30-day Initiation Phase.(IPSD = Index Prescription Start Date). CONTINUOUS ENROLLMENT:
Members must be continuously enrolled for 120 days prior to the IPSD through 30 days after the IPSD.
Rate 2: Continuation and Maintenance (C&M) Phase. The percentage of members 612 years of age as of the IPSD
with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210
days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner
within 270 days (9 months) after the Initiation Phase ended. CONTINUOUS ENROLLMENT: Members must be
continuously enrolled for 120 days prior to the IPSD and 300 days after the IPSD.
Definitions
Intake Period
The 12-month window starting March 1 of the year prior to the measurement year and
ending February 28 of the measurement year.
Negative
Medication
History
A period of 120 days (4 months) prior to the IPSD when the member had no ADHD
medications dispensed for either new or refill prescriptions.
IPSD
Index Prescription Start Date. The earliest prescription dispensing date for an ADHD
medication where the date is in the Intake Period and there is a Negative Medication History.
39
March 2015

Follow-Up Care For Children Prescribed Attention Deficit/Hyperactivity Disorder Medication (contd)
Definitions
MEASURE
Initiation Phase
The 30 days following the IPSD.
C&M Phase
The 300 days following the IPSD (10 months).
New Episode
The member must have a 120-day (4-month) Negative Medication History on or before the
IPSD.
Continuous
Medication
Treatment
The number of medication treatment days during the 10-month follow-up period must be
210 days (i.e., 300 treatment days 90 gap days).
Treatment days
(covered days)
The actual number of calendar days covered with prescriptions within the specified 300-day
measurement interval (e.g., a prescription of a 90 days supply dispensed on the 220th day will
have 80 days counted in the 300-day interval).
Rate 1 Initiation Phase

Event
Follow the steps below to identify the eligible population for the Initiation Phase.
Step 1
Identify all children in the specified age range who were dispensed an ADHD medication (during
the 12-month Intake Period.
Step 2
Test for Negative Medication History. For each member identified in step 1, test each ADHD
prescription for a Negative Medication History. The IPSD is the dispensing date of the earliest
ADHD prescription in the Intake Period with a Negative Medication History.
Step 3
Calculate continuous enrollment. Members must be continuously enrolled for 120 days (4
months) prior to the IPSD through 30 days after the IPSD.
Step 4
Exclude members who had an acute inpatient encounter for mental health or chemical
dependency during the 30 days after the IPSD. An acute inpatient encounter in combination with
any of the following meet criteria:
A principal mental health diagnosis.
A principal diagnosis of chemical dependency.
40
March 2015
Definitions
MEASURE
Initiation Phase
The 30 days following the IPSD.
C&M Phase
The 300 days following the IPSD (10 months).
New Episode
The member must have a 120-day (4-month) Negative Medication History on or before the
IPSD.
Continuous
Medication
Treatment
The number of medication treatment days during the 10-month follow-up period must be
210 days (i.e., 300 treatment days 90 gap days).
Treatment days
(covered days)
The actual number of calendar days covered with prescriptions within the specified 300-day
measurement interval (e.g., a prescription of a 90 days supply dispensed on the 220th day will
have 80 days counted in the 300-day interval).
Rate 1 Initiation Phase

Event
Follow the steps below to identify the eligible population for the Initiation Phase.
Step 1
Identify all children in the specified age range who were dispensed an ADHD medication (during
the 12-month Intake Period.
Step 2
Test for Negative Medication History. For each member identified in step 1, test each ADHD
prescription for a Negative Medication History. The IPSD is the dispensing date of the earliest
ADHD prescription in the Intake Period with a Negative Medication History.
Step 3
Calculate continuous enrollment. Members must be continuously enrolled for 120 days (4
months) prior to the IPSD through 30 days after the IPSD.
Step 4
dependency during the 30 days after the IPSD. An acute inpatient encounter in combination with
any of the following meet criteria:
41
March 2015

Rate 2 C&M Phase
Event
Follow the steps below to identify the eligible population for the C&M Phase.
Step 1
Identify all members who meet the eligible population criteria for Rate 1Initiation Phase.
Step 2
Calculate continuous enrollment. Members must be continuously enrolled in the organization

for 120 days (4 months) prior to the IPSD and 300 days (10 months) after the IPSD.
Step 3
Calculate the continuous medication treatment. Using the members in step 2, determine if the
member filled a sufficient number of prescriptions to provide continuous treatment for at least
210 days out of the 300-day period after the IPSD. The definition of continuous medication
treatment allows gaps in medication treatment, up to a total of 90 days during the 300-day (10month) period. (This period spans the Initiation Phase [1 month] and the C&M Phase [9
months].)
MEASURE
Gaps can include either washout period gaps to change medication or treatment gaps to refill
the same medication.
Regardless of the number of gaps, the total gap days may be no more than 90. The organization
should count any combination of gaps (e.g., one washout gap of 14 days and numerous weekend
drug holidays).
Step 4
dependency during the 300 days (10 months) after the IPSD. An acute inpatient encounter in
combination with any of the following meet criteria:
EXCLUSIONS: Exclude from the denominator for both rates, members with a diagnosis of narcolepsy any time during
their history through December 31 of the measurement year.
42
March 2015

Rate 1: Initiation: An outpatient, intensive outpatient or partial hospitalization follow-up visit with a practitioner
with prescribing authority, within 30 days after the IPSD Members had follow-up care within 30 days following the
IPSD with a prescribing practitioner.
Rate 2 Continuation: Children who remained on the medication for at least 210 days and had 2 follow-up visits
with any practitioner between 31 and 300 days after the IPSD. One of the two visits (during days 31-300) may be a
telephone visit with any practitioner.
Codes to Identify Follow-Up Visits:
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
CPT
HCPCS
REVENUE
90804-90815, 96150-96154, 9896098962, 99078, 99201-99205, 9921199215, 99217-99220, 99241-99245,

99341-99345, 99347-99350, 99383,
99384, 99393, 99394, 99401-99404,
99411, 99412, 99510
G0155, G0176, G0177, G0409G0411, H0002, H0004, H0031,

H0034-H0037, H0039, H0040,
H2000, H2001, H2010-H2020,
M0064, S0201, S9480, S9484,
S9485
0510, 0513, 0515-0517,

0519-0523, 0526-0529, ,
0900, 0902-0905, 0907,
0911-0917, 0919, 0982,
0983
CPT
POS
90801, 90802, 90816-90819, 90821-90824, 90826-90829, 90845, 90847,

90849, 90853, 90857, 90862, 90875, 90876, 90791, 90792, 90832, 90833,
90834, 90836, 90837, 90838, 90839, 90840
WITH
99221-99223, 99231-99233, 99238, 99239, 99251-99255
WITH
Codes to Identify Telephone Visits: CPT: 98966-98968, 99441-99443

Codes to Identify Exclusions: Narcolepsy: ICD9-DIAGS: 347, 347.01, 347.10, 347.11
43
March 2015
03, 05, 07, 09, 11,

12, 13, 14, 15, 20,
22, 33, 49, 50, 52,
53, 71, 72
52, 53

ADHD MEDICATIONS
NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org
by November 1, 2014.
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Description
CNS stimulants
Alpha-2
receptor
agonists
Miscellaneous
ADHD
medications
Prescription
Amphetaminedextroamphetamine
Dexmethylphenidate
Clonidine
Atomoxetine
44
March 2015
Dextroamphetamine
Lisdexamfetamine
Methamphetamine
Guanfacine
methylphenidate

Follow-Up After Hospitalization for Mental Illness (FUH) NOT IN HEALTH e-BLUE
MEASURE
The percentage of discharges for members 6 years of age and older, as of the date of discharge, who were hospitalized
for treatment of selected mental illness diagnoses and who had an outpatient visit, an intensive outpatient encounter
or partial hospitalization with a mental health practitioner. Two rates are reported:
The percentage of discharges for which the member received follow-up within 30 days of discharge.
The percentage of discharges for which the member received follow-up within 7 days of discharge
Continuous Enrollment: Date of discharge through 30 days after discharge.
Event/Diagnosis:
Discharged alive from an acute inpatient setting (including acute care psychiatric facilities) with a
principal mental health diagnosis on or between January 1 and December 1 of the measurement year. Do not use
diagnoses from professional claims to identify discharges; use only facility claims
The denominator for this measure is based on discharges, not members. If members have more than one discharge,
include all discharges on or between January 1 and December 1 of the measurement year.
30 Day Follow-up
7 Day
Follow-up
An outpatient visit, intensive outpatient visit or partial hospitalization with a mental

health practitioner within 30 days after discharge. Include outpatient visits, intensive
outpatient visits or partial hospitalizations that occur on the date of discharge.
An outpatient visit, intensive outpatient visit or partial hospitalization with a mental
health practitioner within 7 days after discharge. Include outpatient visits, intensive
outpatient visits or partial hospitalizations that occur on the date of discharge.
45
March 2015

Follow-up After Hospitalization for Mental Illness (contd)
Codes to Identify Mental Health Diagnosis
ICD9-DIAGS: 290, 293 - 299, 300-302, 301, 306 - 314
Codes to Identify Visits

Follow-up visits identified by the following CPT or HCPCS must be with a mental health practitioner
CPT
HCPCS
90804-90815, 90832-90834, 90836-90840, 98960-98962,
99078, 99201-99205, 99211-99215, 99217-99220, 9924199245, 99341-99345, 99347-99350, 99383-99387, 9939399397, 99401-99404, 99411, 99412, 99510
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
G0155, G0176, G0177, G0409-G0411,

H0002, H0004, H0031, H0034-H0037,
H0039, H0040, H2000, H2001, H2010H2020, M0064, S0201, S9480, S9484,
S9485
Follow-up visits identified by the following CPT/POS codes must be with a mental health
practitioner
CPT
POS
90791, 90792, 90801, 90802, 90816-90819,
90821-90824, 90826-90829, 90832-90834,
90836-90840, 90845, 90847, 90849, 90853,
90857, 90862, 90870, 90875, 90876
99221-99223, 99231-99233, 99238, 99239,
99251-99255
WITH
03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 24,
33, 49, 50, 52, 53, 71, 72
WITH
52, 53
REVENUE
Visits identified by the following revenue codes must be with a mental health practitioner or in
conjunction with a mental health diagnosis code.
0510, 0515-0517, 0519-0523, 0526-0529, 0982, 0983
The organization does not need to determine practitioner type for follow-up visits identified by the
following revenue codes
0513, 0900-0905, 0907, 0911-0917, 0919
46
March 2015

MEDICATION MANAGEMENT
Annual Monitoring for Patients on Persistent Medications (MPM)
MEASURE
The percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory
medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic
monitoring event for the therapeutic agent in the measurement year.
18 years of age and older as of December 31 of the measurement year.
Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor
blockers (ARB)
Annual monitoring for members on digoxin
Annual monitoring for members on diuretics
Medication
Measure
Reporting Target
ACE Inhibitors or ARBs
One Serum Potassium AND a

Serum Creatinine therapeutic
monitoring test.
At least one serum potassium and a serum creatinine

therapeutic monitoring test during the measurement
year. The two tests do not need to occur on the same
service date, only within the measurement year.
Diuretics
Serum Potassium AND a Serum

Creatinine therapeutic
monitoring test.
At least one serum potassium and a serum creatinine

therapeutic monitoring test during the measurement
year. The tests do not need to occur on the same
service date, only within the measurement year.
Digoxin
A Serum Potassium, a Serum

Creatinine AND a serum digoxin
therapeutic monitoring test.
At least one serum potassium, at least one serum

creatinine AND at least one serum digoxin therapeutic
monitoring test during the measurement year. The
tests do not need to occur on the same service date,
only within the measurement year.
For more details on the medications in this measure, please reference the NCQA HEDIS2015 Specifications at
www.ncqa.org.
47
March 2015

Annual Monitoring for Patients on Persistent Medications (contd)
Codes to Identify Physiologic Monitoring Tests for Members on ACE/ARBs, Digoxin and Diuretics
WHAT TO REPORT
Description
Lab Panel
HEDIS 2015
Measurement Codes:
CPT
80047, 80048, 80050, 80053, 80069 (Serum Potassium and serum Creatinine are
included in each panel)
Serum Potassium (K+

Serum Creatinine (SCr)
Serum Digoxin Level
80051, 84132
82565, 82575
80162
Potentially Harmful Drug-Disease Interactions in the Elderly (DDE)

Quality Summary Report Measure Only (No data entry in Treatment Opportunity by Condition/Measure)
MEASURE
MEDICARE ONLY
HEDIS2015 MEDICARE only - for more detail on the medications in this measure, please reference the NCQA 2015 HEDIS
specifications at www.ncqa.org.
Members 67 years of age or older as of December 31 of the measurement year who have evidence of an underlying disease,
condition or health concern and who were dispensed an ambulatory prescription for a potentially harmful medication, concurrent
with or after the diagnosis.
Continuous Enrollment: The measurement year and the year prior to the measurement year
Report each of the three rates separately and as a total rate.

A history of falls and a prescription for anticonvulsants, nonbenzodiazepine hypnotics, SSRIs, antiemetics, antipsychotics,
benzodiazepines or tricyclic antidepressants.
Dementia and a prescription for antiemetics, antipsychotics, benzodiazepines, tricyclic antidepressants, H 2 Receptor Antagonists,
nonbenzodiazepine hypnotics or anticholinergic agents.
Chronic kidney disease and prescription for Cox-2 Selective NSAIDs or nonaspirin NSAIDs.
Total rate (the sum of the three numerators divided by the sum of the three denominators).
Members with more than one disease or condition may appear in the measure multiple times (i.e., in each indicator for which they
qualify). A lower rate represents better performance for all three rates.
These members will display as a not met because they are taking a potentially harmful drug. There is NO data entry for this measure
on Health e-Blue.
48
March 2015

Potentially Harmful Drug-Disease Interactions in the Elderly (contd)
Identification of members on potentially harmful medications with a history of falls and a prescription for tricyclic
antidepressants, antipsychotics, or sleep agents; dementia and a prescription for tricyclic antidepressants or
anticholinergic agents; or CRF and a prescription for nonaspirin NSAIDs or Cox-2 Selective NSAIDs.
Codes to identify falls or hip fractures:
Hip Fracture:
CPT: 27230, 27232, 27235, 27236, 27238, 27240, 27244-27246, 27248, 27254, 27267-27269, 27767-27769
ICD9-DIAGS: 820, V54.13
WHAT TO REPORT
Falls:
ICD9-DIAGS: E880, E884, E885, E887, E888
HEDIS 2015
Measurement Codes:
Codes to identify psychosis:
ICD9-DIAGS: 293, 296, 297, 298,
Codes to identify dementia:

ICD9-DIAGS: 290, 291, 294, 331
Dementia in conditions classified elsewhere with behavioral disturbance:

ICD9-DIAGS: 294.11, 294.21
Codes to identify schizophrenic disorders:

ICD9-DIAGS: 295
49
March 2015

Potentially Harmful Drug-Disease Interactions in the Elderly (contd)
Codes to identify bipolar disorders
ICD9-DIAGS: 296.
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
Codes to Identify seizure disorders

ICD9-DIAGS: 345
Codes to identify chronic renal failure (CRF): (Includes ESRD, CKD stage 4, Kidney Transplant)
CPT: 36147, 36800, 36810, 36815, 36818, 36819-36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370,
50380, 90935, 90937, 90940, 90945, 90947, 90957-90962, 90965, 90966, 90969, 90970, 90989, 90993, 90997, 90999,
99512
HCPCS: G0257, S9339
ICD9-DIAGS: 585.4, 585.5, 585.6, V42.0, V45.1
DRUG PLAN MEDICATION MONITORING CMS Part D Measures

Recommended Blood Pressure Medications for Diabetics with Hypertension
MEASURE
The percentage of Medicare members 18 years of age and older dispensed a medication for diabetes and for hypertension
who were receiving an ACEI or ARB medication which are recommended for people with diabetes.
MEDICARE ONLY
Numerator: Number of enrolled members (18 or older) from the eligible population who received an ACEI or ARB
medication.
Denominator: Number of enrolled members (18 or older) in the measurement period who were dispensed at least one
prescription for an oral hypoglycemic agent or insulin and at least one prescription for an antihypertensive agent
during the measurement period.
50
March 2015
High-Risk Medications in the Elderly

(No data entry in Treatment Opportunity by Condition/Measure)
MEASURE
MEDICARE ONLY
Percentage of Medicare members age 65 and over who received two or more prescription fills for the same high risk drug
with a high risk of serious side effects in the elderly.
Medicare only - for more detail on the medications in this measure, please reference the 2015 Medication Lists on the
Health e-Blue home page.
A lower rate represents better performance.

These members will display as a not met because they are taking one of the high risk medications. There is NO data entry
for this measure.
Medication Adherence to Oral Diabetes Medications
MEASURE
MEDICARE ONLY
The percentage of adult Medicare members who adhere to their prescribed drug therapy across the following classes of
oral diabetes medications; biguanides, sulfonylureas, thiazolidinediones, incretin mimetic, meglititide, and DPP-IV
inhibitors.
Numerator: Number of adult members (18 or older) enrolled during the measurement period with a proportion of
days covered (PDC) at 80% or over across the classes of oral diabetes medications. The PDC is the percent of days in
the measurement period covered by prescription claims across the classes of diabetes meds. Members are excluded if
they have one or more fills for insulin during the measurement period.
Denominator: Number of adult members (18 or older) enrolled during the measurement period with at least two fills
of medication(s) across any of the drug classes of oral diabetes drugs.
51
March 2015
Medication Adherence for Hypertension (RAS Antagonists)

MEASURE
The percentage of adult Medicare members who adhere to their prescribed RAS antagonist drug therapy of an ACEI or
ARB or a direct rennin inhibitor medication.
MEDICARE ONLY
days covered (PDC) at 80% or over for RAS antagonist medications.
Denominator: Number of adult members (18 or older) enrolled during the measurement period with at least two
fills of either the same medication or medications in the same drug class.
Medication Adherence for Cholesterol (Statins)

MEASURE
The percentage of adult Medicare members who adhere to their prescribed drug therapy for statin cholesterol
medications.
MEDICARE ONLY
days covered (PDC) at 80% or over for statin cholesterol medications.
Denominator: Number of adult members (18 or older) enrolled during the measurement period with at least two fills
of either the same statin medication or medications in the same drug class.
52
March 2015

ACCESS AND AVAILABILITY OF CARE
Children and Adolescents Access to Primary Care Practitioners (CAP) NOT IN HEALTH e-BLUE
MEASURE
Percentage of members 12 months 19 years of age who had a visit with a PCP (Physician, nurse practitioner or physician
assistant; licensed practical nurses and registered nurses are not considered PCPs) according to the age band requirements
below.
EXCLUSIONS: None.
Children 12 months 6 years who had a visit with a PCP during the measurement year
Children 7-19 years who had a visit with a PCP during the measurement year or the year prior.
WHAT TO REPORT
Codes to identify visits:

Codes:
Ambulatory E&M codes appropriate to age and service rendered.
Prenatal and Postpartum Care (PPC) NOT IN HEALTH e-BLUE

MEASURE
Percentage of deliveries of live births between November 6 of the year prior to the measurement year and November 5 of
the measurement year. For these women, the measure assesses the following facets of prenatal and postpartum care:
timeliness of prenatal care and postpartum care.
EXCLUSIONS: Deliveries not resulting in live births.
Prenatal visit in the first trimester or within 42 days of enrollment in the organization.
Postpartum visit on or between 21 and 56 days after delivery.
53
March 2015

Prenatal and Postpartum Care (contd)
Prenatal:
A bundled service code on a claim/encounter including the date when prenatal care was initiated.
WHAT TO REPORT
HEDIS 2015
Measurement Codes:
A claim/encounter for prenatal care with a CPT/HCPCS: 99500,0500F,0501F,0502F,H1000,H1001,H1002,H1003,H1004

A claim/encounter for prenatal visit with an ultrasound (echocardiography) or the pregnant uterus or with a principal
pregnancy-related diagnosis code.
Postpartum:
A claim/encounter for a pelvic exam or postpartum care on or between 21 and 56 days after delivery.
A claim/encounter for a bundled service including the date when postpartum care was rendered.
Note: requirement for practitioner specialty only applies to the data collected from the medical record (hybrid
specification).
Adults Access to Preventive/Ambulatory Health Services (AAP) MAPPO Only

MEASURE
Percentage of members 20 years and older who had an ambulatory or preventive care visit according to timeframes below
by product line.
EXCLUSIONS: None.
Medicare or Medicaid members who had an ambulatory or preventive care visit during the measurement year.
Commercial members who had an ambulatory or preventive care visit during the measurement year or the two years prior
to the measurement year.
WHAT TO REPORT
Codes:
Codes to identify visits:

Ambulatory E&M codes appropriate to age and service rendered.
54
March 2015

CMS MILLION HEARTS For Diabetes and Cardiovascular Disease (CVD)
Blue Care Network is implementing a program to prevent cardiovascular disease. The program is designed for BCN
Advantage HMO POS sm and BCNAdvantage HMO sm members, ages 40 and over, who have a history of cardiovascular
disease or diabetes. The focus of the program is to reduce the morbidity and mortality related to cardiovascular disease in
these members.
OVERVIEW
The program incorporates clinical practice guidelines for the management of ischemic heart disease and diabetes mellitus
following the guiding principles behind the nations Million Hearts initiative. Million Hearts is a national initiative to
prevent 1 million heart attacks and strokes over five years. It is led by the U.S. Department of Health and Human Services,
the Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services in partnership with
other federal agencies.
BCN Advantagesm will participate in Million Hearts over five years with 2012 as the baseline measurement year. Results
will be measured and reviewed annually. Interventions will be implemented as needed to improve results.
For Incentive detail please see the 2015 CMS Million Hearts Incentive Program document located on the BCN Health eBlue home page under the Resource/Incentive Documents
For both Diabetes and CVD the following services are needed in the measurement year:
WHAT SERVICES ARE

NEEDED
1.
2.
3.
4.
5.
6.
7.
8.
A1c testing
LDL testing
BP control (<140/90)
Aspirin/anti-platelet therapy
Tobacco cessation
BMI Adult
Statin therapy
ACE/ARB therapy for members with hypertension
55
March 2015
TEST
A1c testing
LDL testing
BP Control (<140/90)
Systolic
CODES
CPT: Like CDC
CPT: Like CDC 2014
CPT II codes:
3074F SBP <130
3075F SBP 130 139
WHAT TO REPORT
Diastolic

Codes:
Aspirin/anti-platelet therapy
Tobacco Cessation
BMI Adult
Statin therapy
ACE/ARB therapy for members with
hypertension
3078F DBP <80

3079F 80 - 89
CPT II code: 4086F
CPT II codes: 4000F, 40004
ICD9DIAGS: V85.0 V85.54
CMS Part D list for Statins
CMS Part D list for ACE/ARBs
PATIENT DEMOGRAPHICS
Race Collection
All Commercial members are included in this measure.

Race must be the member reported race.
The date race was documented in the members medical record should be used and it should be associated with a visit date or an assessment date.
If race is not documented in the chart of the patient refused to supply, then there is nothing to enter into Health e-Blue and the race measure will
remain a not met.
56
March 2015

2015 BCBSM HEDIS Measure Description PDF

Uploaded by

Copyright:

Available Formats

2015 BCBSM HEDIS Measure Description PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

2015 BCBSM HEDIS Measure Description PDF

Uploaded by

Copyright:

Available Formats

2015

2015 HEDIS MEASURE DESCRIPTION

2015 HEDIS MEASURE DESCRIPTION

2015 HEDIS MEASURE DESCRIPTION

2015 HEDIS MEASURE DESCRIPTION

2015 HEDIS MEASURE DESCRIPTION

OVERVIEW OF QUALITY INITIATIVES OF BCBSM AND BCN (contd)

Drug plan customer service

What are CMS Star ratings?

2015 HEDIS MEASURE DESCRIPTION

WHAT SERVICE IS NEEDED

HEDIS 2015 Measurement

Codes to Identify BMI

2015 HEDIS MEASURE DESCRIPTION

WHAT SERVICE IS NEEDED

Codes to Identify Outpatient Visits

Codes to Identify BMI Pediatric Percentile

2015 HEDIS MEASURE DESCRIPTION

Child Immunization Status (CIS)

Members who turn 2 years of age during the measurement year

Measles, Mumps and Rubella (MMR)*

WHAT SERVICE IS NEEDED

2015 HEDIS MEASURE DESCRIPTION

WHAT SERVICE IS NEEDED

2015 HEDIS MEASURE DESCRIPTION

2015 HEDIS MEASURE DESCRIPTION

Adolescent Immunizations (IMA)

WHAT SERVICE IS NEEDED

Members who turn 13 years of age during the measurement year.

2015 HEDIS MEASURE DESCRIPTION

Human Papillomavirus Vaccine for Female Adolescents (HPV)

WHAT SERVICE IS NEEDED

Human Papillomavirus Vaccine (HPV)

Lead Screening in Children (LSC)

WHAT SERVICE IS NEEDED

Lead, quantitative; blood

2015 HEDIS MEASURE DESCRIPTION

Breast Cancer Screening (BCS)

WHAT SERVICE IS NEEDED

Unilateral mastectomy with a bilateral modifier (50)

Two unilateral mastectomies with service dates 14 or more days apart.

2015 HEDIS MEASURE DESCRIPTION

Cervical Cancer Screening (CCS)

Codes to Identify Human Papillomavirus Test

2015 HEDIS MEASURE DESCRIPTION

WHAT SERVICE IS NEEDED

2015 HEDIS MEASURE DESCRIPTION

Chlamydia Screening in Women (CHL)

WHAT SERVICE IS NEEDED

2015 HEDIS MEASURE DESCRIPTION

2015 HEDIS MEASURE DESCRIPTION

WHAT SERVICE IS NEEDED

Preventive Office Visits:

2015 HEDIS MEASURE DESCRIPTION

Designated Provider Specialties for HME

2015 HEDIS MEASURE DESCRIPTION

Continuous Enrollment: Measurement year.

WHAT SERVICE IS NEEDED

Office or other outpatient services (with specific specialty below)